A Phase I Open-Label, Multiple Dose, Sequential Dose Escalation Study to Investigate the Safety and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced and Refractory Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs CUDC 101 (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions; Biomarker
- Sponsors Curis
- 31 Aug 2018 Biomarkers information updated
- 16 Nov 2010 Results will be presented in a poster session at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
- 13 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.